Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
View/ Open
Author
Dalby, Anthony J.
Fox, Keith A. A.
Murphy, Sabina A.
Nicolau, José Carlos
Oude Ophuis, Ton
Spinar, Jindrich
Theroux, Pierre
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1161/JAHA.114.001505Metadata
Show full item recordCitation
Magnani, G., M. P. Bonaca, E. Braunwald, A. J. Dalby, K. A. A. Fox, S. A. Murphy, J. C. Nicolau, et al. 2015. “Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States.” Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease 4 (3): e001505. doi:10.1161/JAHA.114.001505. http://dx.doi.org/10.1161/JAHA.114.001505.Abstract
Background: Vorapaxar is a protease‐activated receptor‐1 antagonist approved by the U.S. Food and Drug Administration (FDA) for the reduction of thrombotic cardiovascular (CV) events in patients with a history of myocardial infarction (MI) and peripheral artery disease (PAD), without a previous stroke or transient ischemic attack (TIA). Methods and Results: We examined the efficacy and safety of vorapaxar in the intended use population, considering 20 170 patients randomized in the multinational, double‐blinded, placebo‐controlled TRA 2°P‐TIMI 50 trial. Of these, 16 897 qualified with a history of MI in the prior 2 weeks to 1 year and 3273 with PAD. At baseline 97% of the patients were treated with aspirin, 71% with a thienopyridine, and 93% a statin. At 3 years, the endpoint of CV death, MI, or stroke was significantly reduced with vorapaxar compared with placebo (7.9% versus 9.5%, HR, 0.80; 95% CI 0.73 to 0.89; P<0.001). Vorapaxar also significantly reduced the composite of CV death, MI, stroke, and urgent coronary revascularization (10.1% versus 11.8%, HR, 0.83; 95% CI 0.76 to 0.90; P<0.001), as well as the rate of CV death or MI (P<0.001). The safety endpoint of GUSTO moderate or severe bleeding, was increased in the vorapaxar group (3.7 versus 2.4, HR, 1.55; 95% CI 1.30 to 1.86, P<0.001). Intracranial bleeding (ICH) was 0.6% versus 0.4%, P=0.10 with vorapaxar versus placebo, with fatal bleeding 0.2% versus 0.2%; P=0.70. Conclusions: In patients with prior MI or PAD who have not had a previous stroke or TIA, vorapaxar added to standard therapy is effective for long‐term secondary prevention of thrombotic CV events, while increasing moderate or severe bleeding. Clinical Trial Registration URL: clinicaltrials.gov Unique Identifier: NCT00526474.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392433/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:15035018
Collections
- HMS Scholarly Articles [17922]
Contact administrator regarding this item (to report mistakes or request changes)